b'Our facility See what small Nanoforms headquarters, R&D and manufacturing are located at the Cultivator IIcan do for youbuilding housed within the Viikki Life Science Parkone of Finlands largest bioscience hubs. The Viikki site fits in with Nanoforms ambitions to expand the current facilities. The certification of GMP status means that the facility represents Initial evaluationthe first GMP nanoforming capability in the world. The growth in capacity has1 We first perform an initial evaluation to understand enabled us to meet the growing demand for formulations with improved solubility compound characteristics.and bioavailability. Additional non-GMP and GMP lines are to be constructedOur extensive conversations with partners enable us to fully define continuously until the end of 2025. We are committed to continual improvement what we aim to achieve and the in the areas of Environmental, Health and Safety (EHS), to ensure compliance challenges involved. with Good Manufacturing Practice (GMP).Proof of conceptand processWe help partners around2 A proof of concept study is initiated to determine the the world by nanoformingfeasibility of nanoforming the material. A proof of process study APIs for a range ofis then performed to find the optimal process parameters for therapeutic areas. consistent, reproducible results.Edward HggstrmCEO3 Technology transferA demonstration batch is produced at a larger scale in preparation for GMP manufacture. 4 GMP manufactureYour product is moved to a GMP facility for clinical production.22 23'